Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas

Annals of Surgical Oncology

Volumn 19, Issue SUPPL. 3, 2012, Pages

  Sonobe, Makoto ^a   Kobayashi, Masashi ^a   Ishikawa, Masashi ^a   Kikuchi, Ryutaro ^a   Nakayama, Ei ^a   Takahashi, Tsuyoshi ^a   Menju, Toshi ^a   Takenaka, Kazumasa ^a   Miyahara, Ryo ^a   Huang, Cheng Long ^a   Okubo, Kenichi ^a   Bando, Toru ^a   Date, Hiroshi ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR; TEGAFUR; URACIL;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CIGARETTE SMOKING; CODON; DISEASE FREE SURVIVAL; DISEASE SEVERITY; EXON; FEMALE; GENE DELETION; GENE INSERTION; GENE MUTATION; GROUPS BY AGE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; POINT MUTATION; RECURRENT CANCER; RETROSPECTIVE STUDY; SEX DIFFERENCE; SURVIVAL TIME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CODON; DISEASE-FREE SURVIVAL; EXONS; FEMALE; GENES, NEOPLASM; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTAGENESIS, INSERTIONAL; NEOPLASM RECURRENCE, LOCAL; POINT MUTATION; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SEQUENCE DELETION; TIME FACTORS;

EID: 84864966574     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1799-8     Document Type: Article

References (35)

1. TJ Lynch DW Bell R Sordella, et al. 2009 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med. 350 2129 2139 10.1056/NEJMoa040938
2. JG Paez PA Janne JC Lee, et al. 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science. 304 1497 1500 15118125 10.1126/science.1099314 1:CAS:528:DC%2BD2cXksVGmsbs%3D
3. W Pao V Miller M Zakowski, et al. 2004 EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci U S A. 101 13306 13311 15329413 10.1073/pnas.0405220101 1:CAS:528:DC%2BD2cXnvFems70%3D
4. P Stephens C Hunter G Bignell, et al. 2004 Lung cancer: intragenic ERBB2 kinase mutations in tumours Nature. 431 525 526 15457249 10.1038/431525b 1:CAS:528:DC%2BD2cXnvFCntLg%3D
5. H Sasaki O Kawano K Endo, et al. 2006 Uncommon V599E BRAF mutations in Japanese patients with lung cancer J Surg Res. 133 203 206 16376942 10.1016/j.jss.2005.10.022 1:CAS:528:DC%2BD28XkvVGjurY%3D
6. Y Samuels Z Wang A Bardelli, et al. 2004 High frequency of mutations of the PIK3CA gene in human cancers Science 304 554 15016963 10.1126/science. 1096502 1:CAS:528:DC%2BD2cXjsVGmsbk%3D
7. T Kosaka Y Yatabe H Endoh H Kuwano T Takahashi T Mitsudomi 2004 Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications Cancer Res. 64 8919 8923 15604253 10.1158/0008-5472.CAN- 04-2818 1:CAS:528:DC%2BD2cXhtVOmsL3P
8. H Shigematsu L Lin T Takahashi, et al. 2005 Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers J Natl Cancer Inst. 97 339 346 15741570 10.1093/jnci/dji055 1:CAS:528:DC%2BD2MXitV2jsb4%3D
9. M Sonobe T Manabe H Wada F Tanaka 2005 Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma Br J Cancer. 93 355 363 16052218 10.1038/sj.bjc.6602707 1:CAS:528: DC%2BD2MXmvFensLY%3D
10. H Minami M Yoshimura Y Miyamoto H Matsuoka N Tsubota 2000 Lung cancer in women: sex-associated differences in survival of patients undergoing resection for lung cancer Chest. 118 1603 1609 11115446 10.1378/chest.118.6.1603 1:STN:280:DC%2BD3M%2FoslKmsQ%3D%3D
11. E Radzikowska P Głaz K Roszkowski 2002 Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases Ann Oncol 13 1087 1093 12176788 10.1093/annonc/mdf187 1:STN:280:DC%2BD38vitFWntg%3D%3D
12. LT Nordquist GR Simon A Cantor WM Alberts G Bepler 2004 Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung Chest. 126 347 351 15302716 10.1378/chest.126.2.347
13. Jancík S, Drábek J, Radzioch D, Hajdúch M. Clinical relevance of KRAS in human cancers. J Biomed Biotechnol. 2010. doi: 10.1155/2010/150960.
14. AS Tsao D Liu JJ Lee M Spitz WK Hong 2006 Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer Cancer. 106 2428 2436 16634096 10.1002/cncr.21884
15. M Sonobe M Nakagawa K Takenaka, et al. 2007 Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer J Surg Oncol. 95 63 69 17192868 10.1002/jso.20547 1:CAS:528:DC%2BD2sXhs12hs7s%3D
16. DA Eberhard BE Johnson LC Amler, et al. 2005 Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol. 23 5900 5909 16043828 10.1200/JCO.2005.02.857 1:CAS:528:DC%2BD2MXhtVKgtbzO
17. DW Bell TJ Lynch SM Haserlat, et al. 2005 Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials J Clin Oncol. 23 8081 8092 16204011 10.1200/JCO.2005.02.7078 1:CAS:528:DC%2BD2MXht1CqsLzM
18. JY Douillard FA Shepherd V Hirsh, et al. 2010 Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial J Clin Oncol. 28 744 752 20038723 10.1200/JCO.2009.24.3030 1:CAS:528:DC%2BC3cXksVyrsbY%3D
19. JL Marks S Broderick Q Zhou, et al. 2008 Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma J Thorac Oncol. 3 111 116 18303429 10.1097/JTO.0b013e318160c607
20. DB Costa S Kobayashi DG Tenen MS Huberman 2007 Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers Lung Cancer. 58 95 103 17610986 10.1016/j.lungcan.2007.05.017
21. TS Mok YL Wu S Thongprasert, et al. 2009 Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med. 361 947 957 19692680 10.1056/NEJMoa0810699 1:CAS:528:DC%2BD1MXhtVygsbfK
22. M Tokumo S Toyooka K Kiura, et al. 2005 The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers Clin Cancer Res. 11 1167 1173 15709185 1:CAS:528:DC%2BD2MXht1ynt7c%3D
23. S Rodenhuis RJ Slebos 1992 Clinical significance of ras oncogene activation in human lung cancer Cancer Res. 52 2665s 2669s 1562997 1:CAS:528:DyaK38XktVGhsLs%3D
24. M Huncharek J Muscat JF Geschwind 1999 K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases Carcinogenesis. 20 1507 1510 10426799 10.1093/carcin/20.8.1507 1:CAS:528:DyaK1MXltlKgu78%3D
25. C Mascaux N Iannino B Martin, et al. 2005 The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis Br J Cancer. 92 131 139 15597105 10.1038/sj.bjc.6602258 1:CAS:528:DC%2BD2MXhtFSjsrs%3D
26. MS Tsao S Aviel-Ronen K Ding, et al. 2007 Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer J Clin Oncol. 25 5240 5247 18024870 10.1200/JCO.2007.12.6953
27. CF Mountain 1997 Revisions in the international system for staging lung cancer Chest. 111 1710 1717 9187198 10.1378/chest.111.6.1710 1:STN:280:DyaK2szjtVOguw%3D%3D
28. Colby TV, Noguchi M, Henshke C, et al. Adenocarcinoma. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. World Health Organization classification of tumours: pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004. p. 35-44.
29. T Antakli RF Schaefer JE Rutherford RC Read 1995 Second primary lung cancer Ann Thorac Surg. 59 863 867 7695410 10.1016/0003-4975(95)00067-U 1:STN:280:DyaK2M3gvFCmtg%3D%3D
30. H Kato Y Ichinose M Ohta, et al. 2004 Adjuvant chemotherapy. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung N Engl J Med. 350 1713 1721 15102997 10.1056/NEJMoa032792 1:CAS:528:DC%2BD2cXjt12mt7c%3D
31. M Maemondo A Inoue K Kobayashi, et al. 2010 Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med. 362 2380 2388 20573926 10.1056/NEJMoa0909530 1:CAS:528:DC%2BC3cXot1Gjt7Y%3D
32. T Mitsudomi S Morita Y Yatabe, et al. 2010 Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol. 11 121 128 20022809 10.1016/S1470-2045(09)70364-X 1:CAS:528:DC%2BC3cXhtlGgtbo%3D
33. T Kosaka Y Yatabe R Onozato H Kuwano T Mitsudomi 2009 Prognostic implication of EGFR KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma J Thorac Oncol. 4 22 29 19096302 10.1097/JTO.0b013e3181914111
34. G Selvaggi S Novello V Torri, et al. 2004 Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small cell lung cancer Ann Oncol. 15 28 32 14679115 10.1093/annonc/mdh011 1:STN:280:DC%2BD3srps1Kntw%3D%3D
35. T Kanematsu S Yano H Uehara Y Bando S Sone 2003 Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients Oncol Res. 13 289 298 12688680